Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

iRhythm Holdings (IRTC) Research & Development (2016 - 2025)

iRhythm Holdings (IRTC) has disclosed Research & Development for 11 consecutive years, with $21.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Research & Development rose 10.3% to $21.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $84.6 million, a 18.4% increase, with the full-year FY2025 number at $84.6 million, up 18.4% from a year prior.
  • Research & Development was $21.0 million for Q4 2025 at iRhythm Holdings, roughly flat from $21.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $21.5 million in Q1 2025 to a low of $8.5 million in Q1 2021.
  • A 5-year average of $16.0 million and a median of $16.0 million in 2023 define the central range for Research & Development.
  • Biggest YoY gain for Research & Development was 43.96% in 2024; the steepest drop was 3.77% in 2024.
  • iRhythm Holdings' Research & Development stood at $8.7 million in 2021, then soared by 37.54% to $11.9 million in 2022, then grew by 29.06% to $15.4 million in 2023, then grew by 23.77% to $19.1 million in 2024, then rose by 10.3% to $21.0 million in 2025.
  • Per Business Quant, the three most recent readings for IRTC's Research & Development are $21.0 million (Q4 2025), $21.0 million (Q3 2025), and $21.0 million (Q2 2025).